Study of Adapted Exercise and Mindfulness Interventions to Improve Motor Function and Sleep Quality in Individuals with Neurodegenerative Disease

Status: Recruiting
Location: See location...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The primary goal of this study is to address the need for targeted therapeutic interventions for impairments that impact walking in related neurodegenerative diseases.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 5
Maximum Age: 75
Healthy Volunteers: t
View:

• The eligibility criteria for males is X-linked adrenoleukodystrophy as determined by biochemical determination or genetic testing.

• The eligibility criteria for females is X-linked adrenoleukodystrophy as determined by biochemical determination, genetic testing, or pedigree analysis.

• The Leukoenceophalopathy with brainstem and spinal cord involvement and lactate elevation inclusion criterion is a confirmed DARS2 mutation through genetic analysis.

• For people with cerebellar ataxia, people with diagnoses of cerebellar damage from stroke, tumor or degeneration will be included. Those with a genetically confirmed cerebellar disorder will be asked to provide their genetic testing to note their particular type of ataxia.

• We will also include patients with other neurodegenerative diseases similar to these disorders as determined by chart review and clinical exam.

⁃ Healthy Volunteers

• Able to stand for 30 seconds without upper extremity support

• Ambulatory (including use of a cane or a walker)

• Able to walk for 2 minutes

Locations
United States
Maryland
Kennedy Krieger Institute
RECRUITING
Baltimore
Contact Information
Primary
Jennifer L Keller, PT, MS
keller@kennedykrieger.org
443-923-2716
Backup
Amena Smith Fine, MD PhD
finea@kennedykrieger.org
443-923-3249
Time Frame
Start Date: 2023-02-13
Estimated Completion Date: 2027-07-30
Participants
Target number of participants: 30
Treatments
Experimental: Home exercise
Individually designed home exercise program
Sponsors
Leads: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

This content was sourced from clinicaltrials.gov